BRPI0411103B1 - método, e, método de obtenção e isolamento de um autoanticorpo de um fluido biológico contendo anticorpo ou de um extrato de fluido biológico contendo anticorpo - Google Patents

método, e, método de obtenção e isolamento de um autoanticorpo de um fluido biológico contendo anticorpo ou de um extrato de fluido biológico contendo anticorpo Download PDF

Info

Publication number
BRPI0411103B1
BRPI0411103B1 BRPI0411103A BRPI0411103A BRPI0411103B1 BR PI0411103 B1 BRPI0411103 B1 BR PI0411103B1 BR PI0411103 A BRPI0411103 A BR PI0411103A BR PI0411103 A BRPI0411103 A BR PI0411103A BR PI0411103 B1 BRPI0411103 B1 BR PI0411103B1
Authority
BR
Brazil
Prior art keywords
plasma
autoantibody
blood
autoantibodies
biological fluid
Prior art date
Application number
BRPI0411103A
Other languages
English (en)
Portuguese (pt)
Inventor
A Mcintyre John
Original Assignee
A Mcintyre John
Redox Reactive Reagents L L C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A Mcintyre John, Redox Reactive Reagents L L C filed Critical A Mcintyre John
Publication of BRPI0411103A publication Critical patent/BRPI0411103A/pt
Publication of BRPI0411103B1 publication Critical patent/BRPI0411103B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/5375—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by changing the physical or chemical properties of the medium or immunochemicals, e.g. temperature, density, pH, partitioning
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/825—Pretreatment for removal of interfering factors from sample
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rehabilitation Therapy (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
BRPI0411103A 2003-06-09 2004-06-09 método, e, método de obtenção e isolamento de um autoanticorpo de um fluido biológico contendo anticorpo ou de um extrato de fluido biológico contendo anticorpo BRPI0411103B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47660703P 2003-06-09 2003-06-09
PCT/US2004/017889 WO2004111608A2 (en) 2003-06-09 2004-06-09 Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions

Publications (2)

Publication Number Publication Date
BRPI0411103A BRPI0411103A (pt) 2006-07-18
BRPI0411103B1 true BRPI0411103B1 (pt) 2019-01-15

Family

ID=33551622

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411103A BRPI0411103B1 (pt) 2003-06-09 2004-06-09 método, e, método de obtenção e isolamento de um autoanticorpo de um fluido biológico contendo anticorpo ou de um extrato de fluido biológico contendo anticorpo

Country Status (9)

Country Link
US (4) US7368542B2 (https=)
EP (1) EP1631314B1 (https=)
JP (1) JP4662557B2 (https=)
CN (1) CN1832756A (https=)
AT (1) ATE518886T1 (https=)
AU (1) AU2004248155B2 (https=)
BR (1) BRPI0411103B1 (https=)
CA (1) CA2524325C (https=)
WO (1) WO2004111608A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892751B2 (en) 2003-06-09 2011-02-22 Redox-Reactive Reagents Llc Method of detecting or diagnosing of a neurodegenerative disease or condition
US9557325B2 (en) * 2003-06-09 2017-01-31 Redox-Reactive Reagents Llc Method of altering the binding specificity of proteins by oxidation-reduction reactions
AU2004248155B2 (en) 2003-06-09 2008-10-23 Redox-Reactive Reagents L.L.C. Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
JP5553963B2 (ja) * 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
KR101322247B1 (ko) * 2007-09-06 2013-10-25 삼성전자주식회사 진공청소기용 흡입브러시 및 그 높이조절방법
MX2010002683A (es) * 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.
US7989596B2 (en) * 2007-09-19 2011-08-02 Redox-Reactive Reagents Llc Method of altering the binding specificity of monoclonal antibodies by oxidation-reduction reactions
JP5565607B2 (ja) 2009-07-15 2014-08-06 国立大学法人 東京大学 敗血症又は多臓器不全の予後診断方法及び予後診断用キット
US20130040844A1 (en) * 2010-01-28 2013-02-14 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers of aging for detection and treatment of disorders
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
WO2017120461A1 (en) 2016-01-08 2017-07-13 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
EP2836845B1 (en) 2012-04-13 2018-05-09 DiabetOmics, Inc. Maternal biomarkers for gestational diabetes
US20150210753A1 (en) 2012-07-26 2015-07-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
WO2014193973A2 (en) 2013-05-28 2014-12-04 Dcb-Usa Llc Antibody locker for the inactivation of protein drug
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
MX2016007492A (es) 2013-12-09 2017-03-06 Univ Leland Stanford Junior Métodos y composiciones para el tratamiento de afecciones asociadas con el envejecimiento.
KR20240025721A (ko) 2015-06-15 2024-02-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 노화와 연관된 질환을 치료하기 위한 방법 및 조성물
KR20180032489A (ko) * 2016-09-22 2018-03-30 아주대학교산학협력단 액상 플라즈마를 이용한 건선의 예방 또는 치료 방법
US11583689B2 (en) * 2016-09-22 2023-02-21 Ajou University Industry-Academic Cooperation Foundation Composition for atopy or psoriasis treatment comprising liquid type plasma
KR20180032490A (ko) * 2016-09-22 2018-03-30 아주대학교산학협력단 액상 플라즈마를 이용한 아토피성 피부염의 예방 또는 치료 방법
KR101933920B1 (ko) 2016-09-22 2018-12-31 아주대학교 산학협력단 액상 플라즈마를 이용한 비만의 예방 또는 치료 방법
EA201991353A1 (ru) 2016-12-09 2019-11-29 Двухвалентные антитела, маскированные спирализованными спиралями
WO2019054836A2 (ko) 2017-09-18 2019-03-21 아주대학교산학협력단 액상 플라즈마를 포함하는 피부 진정용 조성물
EP3955962A4 (en) * 2019-04-18 2022-12-14 Momenta Pharmaceuticals, Inc. SIALYLATED GLYCOPROTEINS
EP3756648A1 (en) * 2019-06-27 2020-12-30 Imnate Sarl Improved vaccine formulations
TR202016418A2 (tr) * 2020-10-14 2022-04-21 Serkan Tunc Kan plazmasinin üzeri̇nden elektri̇k akiminin geçi̇ri̇lmesi̇yle i̇çeri̇si̇nde ölü bakteri̇, parazi̇t vi̇rüs vb. kalintilarin oluştuğu yeni̇ plazmanin canli vücuduna serum olarak veri̇lmesi̇yle bağişiklik geli̇şti̇rme yöntemi̇

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632980A (en) * 1985-04-03 1986-12-30 Immunologics Ozone decontamination of blood and blood products
US4703001A (en) * 1985-10-23 1987-10-27 Synbiotics, Corporation Immunoassay for the detection of serum analytes using pH dependent chastropic acids
US4950612A (en) * 1987-12-16 1990-08-21 Microgenics Corporation Peroxy acid pretreatment in vitamin B12 assay
DE3880477T2 (de) * 1988-02-22 1993-09-16 Fina Research Katalytisches einstufenverfahren zur direkten umwandlung von polysacchariden in mehrwertige alkohole.
US5061790A (en) * 1989-07-10 1991-10-29 Molecular Diagnostics, Inc. Oxidative denaturation of protein analytes
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
US6660267B1 (en) * 1992-12-21 2003-12-09 Promega Corporation Prevention and treatment of sepsis
US5880954A (en) * 1995-12-04 1999-03-09 Thomson; Robert Continous real time safety-related control system
AU703814B2 (en) * 1995-12-04 1999-04-01 Wyeth Antioxidant
US5939394A (en) * 1996-01-18 1999-08-17 Fleming & Company Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections
FR2794461B1 (fr) * 1999-06-07 2004-01-23 Lab Francais Du Fractionnement Procede de preparation de nouvelles fractions d'ig humaines possedant une activite immunomodulatrice
FR2822238B1 (fr) 2001-03-16 2003-08-29 Gemac Methode et trousse pour le suivi des maladies neurodegeneratives
US20040101909A1 (en) 2002-08-20 2004-05-27 Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 Purification of polyreactive autoantibodies and uses thereof
US9557325B2 (en) 2003-06-09 2017-01-31 Redox-Reactive Reagents Llc Method of altering the binding specificity of proteins by oxidation-reduction reactions
AU2004248155B2 (en) 2003-06-09 2008-10-23 Redox-Reactive Reagents L.L.C. Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions

Also Published As

Publication number Publication date
CN1832756A (zh) 2006-09-13
AU2004248155A1 (en) 2004-12-23
CA2524325A1 (en) 2004-12-23
US20080280281A1 (en) 2008-11-13
EP1631314B1 (en) 2011-08-03
EP1631314A2 (en) 2006-03-08
US20160046695A1 (en) 2016-02-18
ATE518886T1 (de) 2011-08-15
US9169317B2 (en) 2015-10-27
JP4662557B2 (ja) 2011-03-30
AU2004248155B2 (en) 2008-10-23
US8334146B2 (en) 2012-12-18
US20130109838A1 (en) 2013-05-02
US10072068B2 (en) 2018-09-11
WO2004111608A2 (en) 2004-12-23
BRPI0411103A (pt) 2006-07-18
US7368542B2 (en) 2008-05-06
WO2004111608A3 (en) 2005-04-07
EP1631314A4 (en) 2006-08-16
JP2006526027A (ja) 2006-11-16
CA2524325C (en) 2017-08-01
WO2004111608A8 (en) 2005-12-29
US20050101016A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
BRPI0411103B1 (pt) método, e, método de obtenção e isolamento de um autoanticorpo de um fluido biológico contendo anticorpo ou de um extrato de fluido biológico contendo anticorpo
Bresnihan et al. Suppressor function of peripheral blood mononuclear cells in normal individuals and in patients with systemic lupus erythematosus.
Denman et al. Adoptive transfer of the diseases of New Zealand black mice to normal mouse strains
McIntyre The appearance and disappearance of antiphospholipid autoantibodies subsequent to oxidation–reduction reactions
US9557325B2 (en) Method of altering the binding specificity of proteins by oxidation-reduction reactions
Harboe et al. Synthesis of donor type γG‐globulin following thymus transplantation in hypo‐γ‐globulinaemia with severe lymphocytopenia
Malheiro et al. Impact of de novo donor‐specific anti‐HLA antibodies on grafts outcomes in simultaneous pancreas–kidney transplantation
Rümke et al. Immunoglobulin production in human mixed lymphocyte cultures: implications for co-cultures of cells from patients and healthy donors.
Nishimaki et al. Studies on immune complexes in rheumatoid arthritis
Van Leeuwen et al. Studies on quinine‐and quinidine‐dependent antibodies against platelets and their reaction with platelets in the Bernard‐Soulier syndrome
US7989596B2 (en) Method of altering the binding specificity of monoclonal antibodies by oxidation-reduction reactions
Penner et al. Immune complexes in primary biliary cirrhosis contain mitochondrial antigens
MXPA05013402A (en) Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
Cantrell et al. Prothrombin prevents fatal T cell–dependent anemia during chronic virus infection of mice
JP6043807B2 (ja) ヒト血液および血液製剤における非定型抗体の同定
McKerns A study on the agglutination of erythrocytes
Miescher inhibiteur de la leucoagglutination 841
Minty The interaction of phagocytic cells with immune complexes in rheumatoid arthritis
CS231763B1 (cs) Sposob přípravy prostriedku pre viazanie protilátek

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: REDOX-REACTIVE REAGENTS L.L.C. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/01/2019, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2623 DE 13-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.